| Makale Türü | Özgün Makale (ESCI dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | Human Gene | ||
| Dergi ISSN | 2773-0441 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | ESCI | ||
| Makale Dili | Türkçe | Basım Tarihi | 12-2023 |
| Cilt / Sayı / Sayfa | 38 / 1 / 1–7 | DOI | 10.1016/j.humgen.2023.201221 |
| Makale Linki | https://doi.org/10.1016/j.humgen.2023.201221 | ||
| Özet |
| Androgen deprivation therapy (ADT) has been the first treatment for advanced prostate cancer. Although 90% of patients initially respond to ADT, the disease inevitably progresses to castration-resistant prostate cancer (CRPC). Docetaxel was reported to provide significant benefit over other chemotherapeutics in prolonging survival in CRPC. Recently, other chemotherapeutics have been used in cases where docetaxel is insufficient or the patient develops resistance, but yet their efficacy is limited. For this reason, it is necessary to develop docetaxel-based therapy, reduce toxicity, increase treatment efficiency. It has been shown that the non-toxic plant lectin Sambucus nigra agglutinin (SNA) drives ovarian cancer cells to the apoptotic pathway. Increased sialic acid levels in prostate cancer have suggested that SNA lectin, which binds to glycan sialic acid residues, may also have an activating effect on the apoptotic … |
| Anahtar Kelimeler |
| Apoptosis | Docetaxel | Plant lectin | Prostate cancer | SNA |
| Atıf Sayıları | |
| Web of Science | 1 |
| Google Scholar | 1 |
| Dergi Adı | Human Gene |
| Yayıncı | Elsevier B.V. |
| Açık Erişim | Hayır |
| ISSN | 2773-0441 |
| E-ISSN | 2773-0441 |
| CiteScore | 1,6 |
| SJR | 0,263 |
| SNIP | 0,267 |